Study of new drug NDI-219216 for advanced solid tumors
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This study tests a new drug called NDI-219216 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are fully active or only slightly limited in daily activities (ECOG score 0 or 1).
- Your cancer has spread and cannot be removed with surgery, and standard treatments no longer work or are not available for you.
- You have at least one tumor that can be measured on scans (this is not required for the first part of the study).
- Your blood counts, organ function (liver, kidneys, etc.), and heart function are adequate.
- Side effects from previous treatments have mostly resolved (except for hair loss, tiredness, or nerve damage).
- You do not have serious heart disease, WRN syndrome, or are pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, CTS2190, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if the drug is safe and effective.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests a new drug called XNW29016 for people with advanced cancer that has stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests an experimental drug called IPN01203 for people with advanced solid tumors that have grown after prior immunotherapy. The goal is to see if the drug is safe and can shrink tumors.
This study tests a new drug called SHR-8203 for people with advanced solid tumors that have stopped responding to standard treatments or have no treatment options. The goal is to see if the drug is safe and helps shrink or control the tumor.
This study tests a new drug (DS5361b) for people with advanced solid tumors that have high genetic instability (TMB-H or MSI-H). It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new MSI-H Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.